Existing levodopa therapies for Parkinson’s disease often provide inadequate symptom control after prolonged treatment. This study assessed the cost-effectiveness of an extended-release carbidopa-levodopa formulation (IPX066).
Andrew Layton, BA
Advertisement
Articles by Andrew Layton, BA
Advertisement
Latest Updated Articles
- Cost-Effectiveness of Extended-Release Carbidopa-Levodopa for Advanced Parkinson's Disease
Published: February 21st 2017 | Updated:
Advertisement
Advertisement
